File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: CD56+ NK lymphomas: Clinicopathological features and prognosis

TitleCD56+ NK lymphomas: Clinicopathological features and prognosis
Authors
Issue Date1997
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJH
Citation
British Journal Of Haematology, 1997, v. 97 n. 4, p. 821-829 How to Cite?
AbstractThe surface molecule CD56 marks a category of malignant lymphoma of putative natural killer (NK) cell origin. We conducted a retrospective analysis of 24 cases of CD56+ NK lymphoma/leukaemia to define the clinicopathologic and prognostic features of this specific group of lymphomas, 56 cases of nasal lymphomas and 204 cases with an initial diagnosis of peripheral T-cell lymphoma were retrospectively analysed. To specifically examine lymphomas of putative NK origin, only those that were negative for surface expression of CD3 but positive for CD56 were analysed, 24 cases were identified. The initial predominant sites of involvement were nasal (n = 18), palate (n = 1), nodal (n = 1) and multi-organ (n = 4). Clinically, in patients with disease localized to one anatomical site (n = 20), most had symptoms confined to the nose, with a high percentage in early stage (I:91%: IV: 9%). The marrow was not involved in any of these cases. However, patients with multi-organ involvement at presentation (n = 4) behaved differently. All presented acutely with pancytopenia, hepatosplenomegaly, and marrow infiltration with haemophagocytosis. A leukaemic phase was observed in one case. Anthracycline containing combination chemotherapy resulted in complete remission in 75% of patients with localized disease, but only in 25% with multi-organ involvement. The median survival of patients with localized disease was 12 months, compared with 2 months in the multi-organ group (P = 0.06); the disease-free survival was significantly better in the former (P < 0.01). The overall median survival of all patients was still poor at 11 months. We conclude that CD56+ NK lymphomas could be divided into two main patterns of disease presentations: localized (predominantly nasal), and multi-organ involvement. Each has different clinicopathologic and prognostic features. Conventional chemotherapy appeared ineffective for the majority of patients, and innovative treatment modalities are needed to improve outcome.
Persistent Identifierhttp://hdl.handle.net/10722/162178
ISSN
2015 Impact Factor: 5.401
2015 SCImago Journal Rankings: 2.313
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_US
dc.contributor.authorChan, ACLen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorChiang, AKSen_US
dc.contributor.authorChim, CSen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorHo, FCSen_US
dc.date.accessioned2012-09-05T05:17:49Z-
dc.date.available2012-09-05T05:17:49Z-
dc.date.issued1997en_US
dc.identifier.citationBritish Journal Of Haematology, 1997, v. 97 n. 4, p. 821-829en_US
dc.identifier.issn0007-1048en_US
dc.identifier.urihttp://hdl.handle.net/10722/162178-
dc.description.abstractThe surface molecule CD56 marks a category of malignant lymphoma of putative natural killer (NK) cell origin. We conducted a retrospective analysis of 24 cases of CD56+ NK lymphoma/leukaemia to define the clinicopathologic and prognostic features of this specific group of lymphomas, 56 cases of nasal lymphomas and 204 cases with an initial diagnosis of peripheral T-cell lymphoma were retrospectively analysed. To specifically examine lymphomas of putative NK origin, only those that were negative for surface expression of CD3 but positive for CD56 were analysed, 24 cases were identified. The initial predominant sites of involvement were nasal (n = 18), palate (n = 1), nodal (n = 1) and multi-organ (n = 4). Clinically, in patients with disease localized to one anatomical site (n = 20), most had symptoms confined to the nose, with a high percentage in early stage (I:91%: IV: 9%). The marrow was not involved in any of these cases. However, patients with multi-organ involvement at presentation (n = 4) behaved differently. All presented acutely with pancytopenia, hepatosplenomegaly, and marrow infiltration with haemophagocytosis. A leukaemic phase was observed in one case. Anthracycline containing combination chemotherapy resulted in complete remission in 75% of patients with localized disease, but only in 25% with multi-organ involvement. The median survival of patients with localized disease was 12 months, compared with 2 months in the multi-organ group (P = 0.06); the disease-free survival was significantly better in the former (P < 0.01). The overall median survival of all patients was still poor at 11 months. We conclude that CD56+ NK lymphomas could be divided into two main patterns of disease presentations: localized (predominantly nasal), and multi-organ involvement. Each has different clinicopathologic and prognostic features. Conventional chemotherapy appeared ineffective for the majority of patients, and innovative treatment modalities are needed to improve outcome.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJHen_US
dc.relation.ispartofBritish Journal of Haematologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntigens, Cd56 - Metabolismen_US
dc.subject.meshAntigens, Neoplasm - Metabolismen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunophenotypingen_US
dc.subject.meshKiller Cells, Natural - Pathologyen_US
dc.subject.meshLymphoma, Non-Hodgkin - Diagnosis - Drug Therapy - Radiotherapyen_US
dc.subject.meshLymphoma, T-Cell, Peripheral - Diagnosis - Drug Therapy - Radiotherapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNose Neoplasms - Diagnosis - Drug Therapy - Radiotherapyen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTumor Markers, Biological - Metabolismen_US
dc.titleCD56+ NK lymphomas: Clinicopathological features and prognosisen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailChiang, AKS:chiangak@hkucc.hku.hken_US
dc.identifier.emailChim, CS:jcschim@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityChiang, AKS=rp00403en_US
dc.identifier.authorityChim, CS=rp00408en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2141.1997.1462962.x-
dc.identifier.pmid9217183-
dc.identifier.scopuseid_2-s2.0-0030762041en_US
dc.identifier.hkuros24717-
dc.identifier.hkuros33101-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030762041&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume97en_US
dc.identifier.issue4en_US
dc.identifier.spage821en_US
dc.identifier.epage829en_US
dc.identifier.isiWOS:A1997XH23800018-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridChan, ACL=16047349300en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridChiang, AKS=7101623534en_US
dc.identifier.scopusauthoridChim, CS=7004597253en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridHo, FCS=7103408147en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats